SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GARY P GROBBEL who wrote (19449)4/5/2004 3:12:03 PM
From: GARY P GROBBEL  Read Replies (1) of 120411
 
PKTX...borrowed this from RB...very basically tells the relationship:

Basically, what they are doing is working with BOCX and while RECAF(BOCX technology) detects the cancer, PKTX is creating the superantibody to kill the cancer once detected. This is directly taken from their quarterly filing dated December 13/03....
In particular, ProtoKinetix will attempt to create a Superantibody that will attach to RECAF molecules. The RECAF molecules with the Superantibody attached are theoretically expected to then attach to cancer cells, with minimal or no harm to non-cancerous cells, so that the Superantibody can destroy the cancer cells. So while BOCX detects the cancer, PKTX is developing for the cure in conjuction with BOCX Recaf technology. As mentioned before, test results are due very soon. Could be a monster week!!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News